Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1991 Jan;35(1):57-61.
doi: 10.1128/AAC.35.1.57.

Aztreonam pharmacokinetics in burn patients

Affiliations
Clinical Trial

Aztreonam pharmacokinetics in burn patients

L V Friedrich et al. Antimicrob Agents Chemother. 1991 Jan.

Abstract

The pharmacokinetics of aztreonam in eight adult patients with severe burn injuries (total body surface area burn, 49% +/- 21% [mean +/- standard deviation]) were studied. The time of initiation of study following burn injury was 7.0 +/- 1.4 days. Four patients at first dose and at steady state were studied. Aztreonam concentrations were measured by high-performance liquid chromatography, and a two-compartment model was used to fit the data. No significant differences in any pharmacokinetic parameters between first dose and steady state were observed. Volume of distribution of the central compartment after first dose (0.14 liters/kg) and volume of distribution at steady state (0.31 liters/kg) were approximately 30% higher than those reported for other patient populations. Total drug clearance and renal drug clearance when normalized to creatinine clearance (CLCR) were similar to those previously reported for other critically ill patients. CLCR was strongly correlated with renal drug clearance (r = 0.94) and total drug clearance (r = 0.95). The extent and degree of burn (percent second or third degree burn) were poorly correlated with all pharmacokinetic parameters with the exception of the volume of distribution at steady state, which was correlated with both total body surface area burn (r = 0.95) and percent second degree burn (r = 0.83). Aztreonam pharmacokinetics are altered as a result of thermal injury; however, CLCR can be used to assess the clearance of aztreonam in burn patients.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Surg Gynecol Obstet. 1970 Jan;130(1):23-8 - PubMed
    1. Clin Pharmacol Ther. 1988 Jul;44(1):9-13 - PubMed
    1. N Engl J Med. 1978 Oct 26;299(17):915-9 - PubMed
    1. Surgery. 1978 Nov;84(5):603-8 - PubMed
    1. Clin Pharmacol Ther. 1979 Mar;25(3):340-4 - PubMed

Publication types